[1]钟春元,陈祚和,邱成旭,等.2型糖尿病患者C11orf 65基因rs11212617位点多态性与二甲双胍临床疗效相关性研究*[J].陕西医学杂志,2018,(12):1565-1567.
　Zhong Chunyuan,Chen Zuohe,Qiu Chengxu,et al.Association between C11orf 65 rs11212617 polymorphisms and clinical efficacy of metformin in type 2 diabetes mellitus[J].,2018,(12):1565-1567.
点击复制

2型糖尿病患者C11orf 65基因rs11212617位点多态性与二甲双胍临床疗效相关性研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2018年12期
页码:
1565-1567
栏目:
临床研究
出版日期:
2018-12-31

文章信息/Info

Title:
Association between C11orf 65 rs11212617 polymorphisms and clinical efficacy of metformin in type 2 diabetes mellitus
文章编号:
DOI:10.3969/j.issn.1000-7377.2018.12.015
作者:
钟春元1; 陈祚和1; 邱成旭1; 杨守东2△
1.江西省兴国县人民医院（兴国 342400），2.内蒙古包钢医院药剂科（包头014010）
Author(s):
Zhong Chunyuan;  Chen Zuohe;  Qiu Chengxu;  et al.
Department of Pharmacy, Xingguo County People's Hospital in Jiangxi Province(Xingguo 342400)
关键词:
#NULL!
Keywords:
Key words ＠C11orf 65 gene Diabetes mellitus; type 2/immunology Metformin Polymorphism; Genetic
分类号:
R587.1
文献标志码:
A
摘要:
摘 要 目的：探讨2型糖尿病（T2DM）患者C11orf 65基因rs11212617位点多态性与二甲双胍单药治疗后临床降糖疗果的相关性。方法：入组180位新发T2DM患者为研究对象，用PCR-限制性片段长度多态性（PCR-RFLP）的方法检测C11orf 65基因rs11212617位点多态性，分析位点突变在研究人群中的分布频率。入组患者服用二甲双胍单药治疗T2DM，经12个月的随访，根据入组患者人群的基因型进行分组，分析糖化血红蛋白（HbA1c）在治疗前后的变化情况，并和各基因型的关系进行统计分析。结果：C11orf 65基因rs11212617 AA基因型与CA和CC基因型HbA1c在治疗前后变化差异具有统计学意义（P<0.01）。结论：C11orf 65基因rs11212617多态性与T2DM患者二甲双胍降糖疗效有一定相关性。
Abstract:
Abstract Objective: To investigate the relationship of C11orf 65 rs11212617 polymorphisms and efficacy of metformin in type 2 diabetes mellitus (T2DM) patients. Methods: A total of 180 patients diagnosed T2DM were enrolled in this study.The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was employed to test the distribution frequency of genetic polymorphism site mutations in this study population.All patients oral metformin therapy T2DM, followed up for 12 months, according to the study population grouping genotypes, analysis of glycosylated hemoglobin (HbA1c), the change of the before and after treatment and the relationship of each genotype. Results: Compared with AA genotype, C11orf 65 rs11212617 CA and CC genotyped patients showed significant decrease of HbA1c (P<0.05). Conclusion: The C11orf 65 rs11212617 polymorphisms may associate with the efficacy of metformin in patients with T2DM.

参考文献/References:


[1] 母义明, 纪立农, 宁 光, 等. 二甲双胍临床应用专家共识(2016年版)[J]. 中国糖尿病杂志, 2016, 24(10):871-884.
[2] Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin[J]. Clinical Pharmacokinetics, 2011, 50(2):81.
[3] van Leeuwen N, Nijpels G, Becker ML, et al. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts[J]. Diabetologia,2012,55(7):1971-1977.
[4] 贾伟平. 中国2型糖尿病防治指南(2017年版)[J]. 中华医学会糖尿病学分会, 2017.
[5] Sambol NC, Chiang J, O'Conner M, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus[J]. Journal of Clinical Pharmacology, 2013, 36(11):1012-1021.
[6] Choi JH ,Yee SW, Kim MJ, et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1[J]. Pharmacogenomics, 2009 ,19: 770-780.
[7] Kang HJ, Lee SS, Lee CH, et al. Neurotoxic pyridinium metabolites of haloperidol are substrates of human organic cation transporters[J]. Drug MetabDispos, 2006,34 :1145-1151.
[8] Fazlollah S, Hamid G, Soudeh G F, et al. Impact of ATM and SLC22A1 polymorphisms on therapeutic response to metformin in iranian diabetic patients[J]. International Journal of Molecular & Cellular Medicine, 2016, 5(1):1-7.

备注/Memo

备注/Memo:
*江西省赣州市卫生和计划生育委员会科研项目（2016-2-60）
更新日期/Last Update: 2019-01-21